Scientists pioneer new antimicrobial drugs from food by-products
Scientists are set to harness the potential of food by-products to manufacture antimicrobial drugs from bacteria.
AstraZeneca to invest £650m in UK’s life sciences sector
Pharmaceutical giant AstraZeneca has revealed plans to inject £650m into the UK, bolstering the nation's life sciences sector and propelling economic growth.
This significant investment...
Pharmaceutical pollution – the blue healthcare revolution
Dr Kelly Thornber, Post-Doctoral Research Fellow at the University of Exeter, discusses the key drivers of pharmaceutical pollution and its impact.
In 2020 the UK’s...
Defence Therapeutics granted US patent for AccuTOX® technology
Defence Therapeutics has achieved a significant milestone with the granting of US patent no. 11,890,350 ('350) by the United States Patent and Trademark Office...
NHS rapidly rolls out new graft versus host disease treatment
The NHS has announced it will fast-track a groundbreaking therapy called Belumosudil to treat graft versus host disease.
Anti-diabetic drugs may lower brain cancer risk, says the University of Bristol
Researchers from the University of Bristol have uncovered a potential link between long-term use of certain anti-diabetic drugs and a reduced risk of primary...
NHS offers groundbreaking portable drug infusion for advanced Parkinson’s disease patients
Hundreds of NHS patients grappling with advanced Parkinson's disease are poised to experience relief thanks to a groundbreaking portable drug infusion set to revolutionise...
Tohoku University develops monoclonal antibody for HER2-positive breast cancer
Tohoku University have engineered a groundbreaking monoclonal antibody aimed at HER2-positive breast cancer.
The critical vaccine cold chain
Dr Nenad Miljković from the European Association of Hospital Pharmacists (EAHP) outlines the critical role of cold chain storage in maintaining the efficacy and...
Over 500,00 women access affordable hormone replacement therapy through HRT PPC
Over 500,000 women in England have accessed more affordable hormone replacement therapy (HRT), the primary treatment for menopause symptoms.
BioNxt acquires cutting-edge equipment to boost drug delivery product manufacturing
BioNxt Solutions Inc. has proudly announced the acquisition of advanced coating and cutting equipment, marking a crucial stride in expanding its commercial manufacturing of...
Defence Therapeutics’ breakthrough in cancer treatment: AccuTOX® shows promise against lung tumours
Defence Therapeutics has announced the successful testing of a new formulation of its ACCUM-002TM Dimer CDCA-SV40 against lung tumours.
Developing mRNA vaccine technology
Following the unprecedented development of vaccines during the COVID-19 pandemic, we spoke to Dinah Knotts about mRNA vaccine technology and what further opportunities it...
Defence Therapeutics granted FDA approval for Phase I Clinical Trial of AccuTOX®
Defence Therapeutics has announced a pivotal milestone: the U.S. Food and Drug Administration (FDA) has granted a green light with a "Study May Proceed"...
NHS approves life-saving Sebelipase alfa treatment for Wolman disease
The NHS has approved a life-saving treatment for babies and toddlers grappling with a rare and fatal genetic condition known as Wolman disease.
This marks...
Defence Therapeutics applies to use AccuTOX® as an advanced tumour treatment
Defence Therapeutics has submitted an Investigational New Drug application for AccuTOX®, an injectable anticancer molecule.
Defence Therapeutics awarded CIPO patent for vaccine technology
Defence Therapeutics has announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for the company's Canadian patent application no....
RECOVERY trial set to investigate revolutionary new flu treatments
The groundbreaking RECOVERY trial, celebrated for its discovery of four effective treatments for COVID-19, is broadening its horizons by venturing into the realm of...
AccuTOX® anticancer drug demonstrates exciting antigen cross-presentation
Defence Therapeutics Inc., a prominent Canadian biopharmaceutical company renowned for its work in immune-oncology vaccines and drug delivery technologies, has announced the discovery of...
Administration of AccuTOX™-chitosan inhibits the growth of established solid lymphoma in animals
Defence Therapeutics has announced that systemic administration of novel AccuTOX™-chitosan encapsulated formulation inhibits the growth of pre-established solid lymphoma resulting in their progressive shrinking...
